BRPI0516935A - secretagogos de gh e usos dos mesmos - Google Patents

secretagogos de gh e usos dos mesmos

Info

Publication number
BRPI0516935A
BRPI0516935A BRPI0516935-6A BRPI0516935A BRPI0516935A BR PI0516935 A BRPI0516935 A BR PI0516935A BR PI0516935 A BRPI0516935 A BR PI0516935A BR PI0516935 A BRPI0516935 A BR PI0516935A
Authority
BR
Brazil
Prior art keywords
individual
improvement
condition
impaired
parameter
Prior art date
Application number
BRPI0516935-6A
Other languages
English (en)
Inventor
Thierry Abribat
Villers Andre De
Soraya Allas
Denis Gravel
Alcides Chapdelaine
Original Assignee
Theratechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/969,463 external-priority patent/US7316997B2/en
Application filed by Theratechnologies Inc filed Critical Theratechnologies Inc
Priority claimed from PCT/CA2005/001611 external-priority patent/WO2006042408A1/en
Publication of BRPI0516935A publication Critical patent/BRPI0516935A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SECRETAGOGOS DE GH E USOS DOS MESMOS. A invenção se refere ao uso de um secretagogo de GH (por exemplo, GRF ou um análogo do mesmo) para (1) alteração de um parâmetro lipídico em um indivíduo; (2) alteração de um parâmetro de composição corporal em um indivíduo, (3) tratamento de uma condição caracterizada por formação óssea deficiente ou diminuída em um indivíduo (4) melhora da vigilância diurna e/ou função cognitiva em um indivíduo, (5) melhora de uma condição metabólica em um indivíduo, (6) melhora do anabolismo em uma condição catabólica em um indivíduo e/ou (7) melhora de e/ou reconstituição da função imune em um indivíduo.
BRPI0516935-6A 2004-10-20 2005-10-20 secretagogos de gh e usos dos mesmos BRPI0516935A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/969,463 US7316997B2 (en) 2003-05-29 2004-10-20 GH secretagogues and uses thereof
CA2485472A CA2485472C (en) 2004-10-20 2004-10-20 Gh secretagogues and uses thereof
PCT/CA2005/001611 WO2006042408A1 (en) 2004-10-20 2005-10-20 Gh secretagogues and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0516935A true BRPI0516935A (pt) 2008-09-23

Family

ID=36242546

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516935-6A BRPI0516935A (pt) 2004-10-20 2005-10-20 secretagogos de gh e usos dos mesmos

Country Status (4)

Country Link
BR (1) BRPI0516935A (pt)
CA (1) CA2485472C (pt)
HK (1) HK1115803A1 (pt)
MX (1) MX2007004682A (pt)

Also Published As

Publication number Publication date
CA2485472A1 (en) 2006-04-20
MX2007004682A (es) 2007-07-17
HK1115803A1 (en) 2008-12-12
CA2485472C (en) 2011-09-27

Similar Documents

Publication Publication Date Title
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
NO20034230D0 (no) 1,2,3,4-tetrahydroisokinolin-derivater som urotensin II reseptor-antagonister
BR0315645A (pt) Polipetìdeos de fusão de actrib e seus usos
WO2006103037A3 (de) ZUSAMMENSETZUNG ENTHALTEND β-DEFENSIN 2
MXPA05002991A (es) Analogos de ghrh.
HUP0303596A2 (hu) Cinkmentes és cinkben szegény, javított stabilitású inzulinkészítmények
DOP2002000429A (es) Imidazotriazinas
SG145712A1 (en) Crystalline tumor necrosis factor receptor 2 polypeptides
HUP0301003A2 (hu) Kazeinből származó peptidek és terápiás alkalmazásuk
EA200100872A1 (ru) Композиция валдекоксиба
BR9914360A (pt) N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5
AU2002351593A1 (en) Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
ATE313562T1 (de) Antimicrobielle wirkung des ersten kationischen cluster des menschlichen lactoferrins
BR0116060A (pt) Composição farmacêutica de dronedarona para administração parenteral
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
ATE476195T1 (de) Zubereitungen von pro-insulin-c-peptid mit verzögerter freisetzung
MXPA02006511A (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido.
BRPI0516935A (pt) secretagogos de gh e usos dos mesmos
ATE458004T1 (de) Osteoprotegerin in milch
WO2001051511A3 (de) Rekombinante herstellung von humanen histon 1-subtypen sowie deren verwendung für therapeutische zwecke
BR9811907A (pt) Proteìna de ligação de lactoferrina de neisseria
RS60604A (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
DE60036199D1 (de) Proteaseresistente flint-analoge
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
MY138502A (en) Novel alkansulfonamides as endothelin antagonists

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07D Technical examination (opinion) related to article 229 of industrial property law

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements